234 related articles for article (PubMed ID: 8874380)
21. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
22. [Phenotype--genotype--correlation in ovarian neoplasia].
Diebold J
Verh Dtsch Ges Pathol; 2001; 85():153-60. PubMed ID: 11894392
[TBL] [Abstract][Full Text] [Related]
23. Ovarian epithelial tumors of low malignant potential: are they precursors of ovarian carcinoma?
Fukumoto M; Nakayama K
Pathol Int; 2006 May; 56(5):233-9. PubMed ID: 16669871
[TBL] [Abstract][Full Text] [Related]
24. The proliferative activity of ovarian tumors of low malignant potential differs from that of ovarian carcinoma.
Nakayama K; Takebayashi Y; Hata K; Fujiwaki R; Iida K; Fukumoto M; Miyazaki K
Anticancer Res; 2003; 23(6C):4657-62. PubMed ID: 14981910
[TBL] [Abstract][Full Text] [Related]
25. Expression of extracellular matrix proteins in ovarian serous tumors.
Salani R; Neuberger I; Kurman RJ; Bristow RE; Chang HW; Wang TL; Shih IeM
Int J Gynecol Pathol; 2007 Apr; 26(2):141-6. PubMed ID: 17413980
[TBL] [Abstract][Full Text] [Related]
26. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
27. Sjögren's syndrome and MALT lymphomas of salivary glands: a DNA-cytometric and interphase-cytogenetic study.
Ihrler S; Baretton GB; Menauer F; Blasenbreu-Vogt S; Löhrs U
Mod Pathol; 2000 Jan; 13(1):4-12. PubMed ID: 10658904
[TBL] [Abstract][Full Text] [Related]
28. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Brustmann H
Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
[TBL] [Abstract][Full Text] [Related]
29. Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone.
Alers JC; Krijtenburg PJ; Rosenberg C; Hop WC; Verkerk AM; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
Lab Invest; 1997 Nov; 77(5):437-48. PubMed ID: 9389787
[TBL] [Abstract][Full Text] [Related]
30. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
Zheng W; Luo MP; Welt C; Lambert-Messerlian G; Sung CJ; Zhang Z; Ying SY; Schneyer AL; Lauchlan SC; Felix JC
Gynecol Oncol; 1998 Apr; 69(1):23-31. PubMed ID: 9570994
[TBL] [Abstract][Full Text] [Related]
31. Interphase fluorescence in situ hybridization studies of ovarian adenocarcinomas using the midisatellite probe.
Kalir T; Eisberg A; Dottino P; Cohen C
Gynecol Oncol; 1999 Feb; 72(2):208-14. PubMed ID: 10021303
[TBL] [Abstract][Full Text] [Related]
32. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
Sangoi AR; McKenney JK; Dadras SS; Longacre TA
Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
[TBL] [Abstract][Full Text] [Related]
33. Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization.
Baretton GB; Valina C; Vogt T; Schneiderbanger K; Diebold J; Löhrs U
Cancer Res; 1994 Aug; 54(16):4472-80. PubMed ID: 8044798
[TBL] [Abstract][Full Text] [Related]
34. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
35. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
36. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease.
Kim SW; Kim JW; Kim YT; Kim JH; Kim S; Yoon BS; Nam EJ; Kim HY
Genes Chromosomes Cancer; 2007 Jan; 46(1):1-9. PubMed ID: 17044060
[TBL] [Abstract][Full Text] [Related]
37. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
38. Genomic alterations in fallopian tube carcinoma: comparison to serous uterine and ovarian carcinomas reveals similarity suggesting likeness in molecular pathogenesis.
Pere H; Tapper J; Seppälä M; Knuutila S; Butzow R
Cancer Res; 1998 Oct; 58(19):4274-6. PubMed ID: 9766651
[TBL] [Abstract][Full Text] [Related]
39. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
40. Copy number aberrations in benign serous ovarian tumors: a case for reclassification?
Hunter SM; Anglesio MS; Sharma R; Gilks CB; Melnyk N; Chiew YE; deFazio A; ; Longacre TA; Huntsman DG; Gorringe KL; Campbell IG
Clin Cancer Res; 2011 Dec; 17(23):7273-82. PubMed ID: 21976534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]